Eyebright Medical Technology (Beijing) Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Eyebright Medical Technology (Beijing) (SHSE:688050) Second Quarter 2024 Results

Key Financial Results

• Revenue: CN¥375.3m (up 73% from 2Q 2023).
• Net income: CN¥105.1m (up 24% from 2Q 2023).
• Profit margin: 28% (down from 39% in 2Q 2023). The decrease in margin was driven by higher expenses.
• EPS: CN¥0.56 (up from CN¥0.44 in 2Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Eyebright Medical Technology (Beijing) Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 16%. Earnings per share (EPS) missed analyst estimates by 74%.

Looking ahead, revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Medical Equipment industry in China.

Performance of the Chinese Medical Equipment industry.

The company's shares are down 7.1% from a week ago.

Risk Analysis

Be aware that Eyebright Medical Technology (Beijing) is showing 1 warning sign in our investment analysis that you should know about...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.